Prognostic factors for resectable pancreatic adenocarcinoma;Facteurs pronostiques de l'adénocarcinome pancréatique résécable

Journal de Chirurgie Viscerale

Volumn 148, Issue 4, 2011, Pages 264-276

  Neuzillet, C ^a   Sauvanet, A ^a   Hammel, P ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Pancreatic adenocarcinoma; Pancreatic cancer; Prognosis; Surgery; Survival

Indexed keywords

EID: 80555139012     PISSN: 1878786X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchirv.2011.06.003     Document Type: Short Survey

References (106)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60(5):277-300.
2. Wray CJ, Ahmad SA, Matthews JB, Lowy AM. Surgery for pancreatic cancer: Recent controversies and current practice. Gastroenterology 2005;128(6):1626-41.
3. Garcea G, Dennison AR, Pattenden CJ, Neal CP, Sutton CD, Berry DP. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP 2008;9(2):99-132.
4. Zacharias T, Jaeck D, Oussoultzoglou E, Neuville A, Bachellier P. Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas. J Gastrointest Surg 2007;11(3):350-6.
5. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients Ann Surg 1995;221(6):721-31 [discussion 31-3].
6. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of the pancreas- 616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4(6):567-79.
7. Cress RD, Yin D, Clarke L, Bold R, Holly EA. Survival among patients with adenocarcinoma of the pancreas: A population-based study (United States). Cancer Causes Control 2006;17(4):403-9.
8. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: A population-based, linked database analysis of 396 patients. Ann Surg 2003;237(1):74-85.
9. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004;91(5):586-94.
10. Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie R, et al. Prognostic factors in resected pancreatic adenocarcinoma: Analysis of actual 5-year survivors. J Am Coll Surg 2004;198(5):722-31.
11. Perini MV, Montagnini AL, Jukemura J, Penteado S, Abdo EE, Patzina R, et al. Clinical and pathologic prognostic factors for curative resection for pancreatic cancer. HPB (Oxford) 2008;10(5):356-62.
12. Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Buchler MW, Friess H, Martignoni ME. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg 2008;12(7):1193-201.
13. Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: Is cure possible? Ann Surg 2008;247(3):456-62.
14. Ueda M, Endo I, Nakashima M, Minami Y, Takeda K, Matsuo K, et al. Prognostic factors after resection of pancreatic cancer. World J Surg 2009;33(1):104-10.
15. Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 2009;13(7):1337-44.
16. Delpero JR, Paye F, Bachellier P.Cancer du Pancréas. Monographies de l'Association Française de Chirurgie. Paris: Wolters Kluwer France; 2010.
17. Magistrelli P, Antinori A, Crucitti A, La Greca A, Masetti R, Coppola R, et al. Prognostic factors after surgical resection for pancreatic carcinoma. J Surg Oncol 2000;74(1): 36-40.
18. Iacono C, Accordini S, Bortolasi L, Facci E, Zamboni G, Montresor E, et al. Results of pancreaticoduodenectomy for pancreatic cancer: Extended versus standard procedure. World J Surg 2002;26(11):1309-14.
19. Diener MK, Heukaufer C, Schwarzer G, Seiler CM, Antes G, Buchler MW, et al. Pancreaticoduodenectomy (classic Whipple) versus pylorus-preserving pancreaticoduodenectomy (pp Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst Rev 2008;(2):CD006053.
20. Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C, et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: A multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998;228(4):508-17.
21. Nimura YNM, Kato H, Miyagawa S, et al. Regional versus extended lymph node dissection in radical pancreaticoduodenectomy for pancreatic cancer. A multicenter randomized controlled trial. HPB (Oxford) 2004;6:2.
22. Riall TS, Cameron JL, Lillemoe KD, Campbell KA, Sauter PK, Coleman J, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma - part 3: update on 5-year survival. J Gastrointest Surg 2005;9(9):1191-204 [discussion 204-6].
23. Farnell MB, Aranha GV, Nimura Y, Michelassi F. The role of extended lymphadenectomy for adenocarcinoma of the head of the pancreas: Strength of the evidence. J Gastrointest Surg 2008;12(4):651-6.
24. Doi R, Kami K, Ito D, Fujimoto K, Kawaguchi Y, Wada M, et al. Prognostic implication of para-aortic lymph node metastasis in resectable pancreatic cancer. World J Surg 2007;31(1):147-54.
25. Hellan M, Sun CL, Artinyan A, Mojica-Manosa P, Bhatia S, Ellenhorn JD, et al. The impact of lymph node number on survival in patients with lymph node-negative pancreatic cancer. Pancreas 2008;37(1):19-24.
26. Fortner JG, KimDK, Cubilla A, Turnbull A, Pahnke LD, Shils ME. Regional pancreatectomy: En bloc pancreatic, portal vein and lymph node resection. Ann Surg 1977;186(1):42-50.
27. Tseng JF, Tamm EP, Lee JE, Pisters PW, Evans DB. Venous resection in pancreatic cancer surgery. Best Pract Res Clin Gastroenterol 2006;20(2):349-64.
28. Fukuda S, Oussoultzoglou E, Bachellier P, Rosso E, Nakano H, Audet M, et al. Significance of the depth of portal vein wall invasion after curative resection for pancreatic adenocarcinoma. Arch Surg 2007;142(2):172-9 [discussion 80].
29. Chun YS, Milestone BN, Watson JC, Cohen SJ, Burtness B, Engstrom PF, et al. Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol 2010;17(11):2832-8.
30. Sasson AR, Hoffman JP, Ross EA, Kagan SA, Pingpank JF, Eisenberg BL. En bloc resection for locally advanced cancer of the pancreas: Is it worthwhile? J Gastrointest Surg 2002;6(2):147-57 [discussion 57-8].
31. Garcea G, Dennison AR, Ong SL, Pattenden CJ, Neal CP, Sutton CD, et al. Tumour characteristics predictive of survival following resection for ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 2007;33(7):892-7.
32. Howard TJ, Krug JE, Yu J, Zyromski NJ, Schmidt CM, Jacobson LE, et al. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer. J Gastrointest Surg 2006;10(10):1338-45 [discussion 45-6].
33. Schmidt CM, Powell ES, Yiannoutsos CT, Howard TJ, Wiebke EA, Wiesenauer CA, et al. Pancreaticoduodenectomy: A 20-year experience in 516 patients. Arch Surg 2004;139(7):718-25 [discussion 25-7].
34. Strumper-Groves D. Perioperative blood transfusion and outcome. Curr Opin Anaesthesiol 2006;19(2):198-206.
35. Jagoditsch M, Pozgainer P, Klingler A, Tschmelitsch J. Impact of blood transfusions on recurrence and survival after rectal cancer surgery. Dis Colon Rectum 2006;49(8):1116-30.
36. Laurent C, Sa Cunha A, Couderc P, Rullier E, Saric J. Influence of postoperative morbidity on long-term survival following liver resection for colorectal metastases. Br J Surg 2003;90(9):1131-6.
37. Schiesser M, Chen JW, Maddern GJ, Padbury RT. Perioperative morbidity affects long-term survival in patients following liver resection for colorectal metastases. J Gastrointest Surg 2008;12(6):1054-60.
38. Tanaka K, Kumamoto T, Nojiri K, Matsuyama R, Takeda K, Endo I. Impact of postoperative morbidity on long-term survival after resection for colorectal liver metastases. Ann Surg Oncol 2010 [Epub ahead of print].
39. Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 2006;10(4):511-8.
40. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Med 2010;7(4):e1000267.
41. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120(8):899-903.
42. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230(6):776-82 [discussion 82-4].
43. Smeenk HG, van Eijck CH, Hop WC, Erdmann J, Tran KC, Debois M, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg 2007;246(5):734-40.
44. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial. Lancet 2001;358(9293):1576-85.
45. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350(12):1200-10.
46. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007;297(3):267-77.
47. Neuhaus PRH, Post S, Gellert K, et al. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer. J Clin Oncol 2008;26 [abstr LBA4504].
48. Regine WFWK, Abrams R, Safran H, Hoffman JP, Konski A, et al. RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. J Clin Oncol 2006;24:4007.
49. Neoptolemos JBM, Stocken DD, Ghaneh P, et al. ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol 2009;27 [abstr LBA4505].
50. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA 2010;304(10):1073-81.
51. Corsini MM, Miller RC, Haddock MG, Donohue JH, Farnell MB, Nagorney DM, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: The Mayo Clinic experience (1975-2005). J Clin Oncol 2008;26(21):3511-6.
52. Hsu CC, Herman JM, Corsini MM, Winter JM, Callister MD, Haddock MG, et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: The Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 2010;17(4):981-90.
53. Van Laethem JL, Hammel P, Mornex F, Azria D, Van Tienhoven G, Vergauwe P, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: A randomized EORTC- 40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol 2010;28(29):4450-6.
54. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25.
55. Morganti AG, Massaccesi M, La Torre G, Caravatta L, Piscopo A, Tambaro R, et al. A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol 2010;17(1):194-205.
56. Kim YE, Park MS, Hong HS, Kang CM, Choi JY, Lim JS, et al. Effects of neoadjuvant combined chemotherapy and radiation therapy on the CT evaluation of resectability and staging in patients with pancreatic head cancer. Radiology 2009;250(3):758-65.
57. Takahashi H, Ohigashi H, Ishikawa O, Eguchi H, Gotoh K, Yamada T, et al. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival. Ann Surg 2010;251(3):461-9.
58. Le Scodan R, Mornex F, Girard N, Mercier C, Valette PJ, Ychou M, et al. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: Feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Ann Oncol 2009;20(8):1387-96.
59. Hernandez JM, Morton CA, Al-Saadi S, Villadolid D, Cooper J, Bowers C, et al. The natural history of resected pancreatic cancer without adjuvant chemotherapy. Am Surg 2010;76(5):480-5.
60. Lee MK, Dinorcia J, Reavey PL, Holden MM, Genkinger JM, Lee JA, et al. Pancreaticoduodenectomy can be Performed Safely in Patients Aged 80 years and Older. J Gastrointest Surg 2010;14(11):1838-46.
61. Marechal R, Demols A, Gay F, de Maertelaer V, Arvanitaki M, Hendlisz A, et al. Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer. Pancreas 2008;36(3):e16-21.
62. Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 2006;10(9):1199-210 [discussion 210-1].
63. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346(15):1128-37.
64. Fong Y, Gonen M, Rubin D, Radzyner M, Brennan MF. Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg 2005;242(4):540-4 [discussion 4-7].
65. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez- delCastillo C, Warshaw AL. Perioperative CA19- 9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006;24(18):2897-902.
66. Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, et al. Tumor markers in pancreatic cancer: A European Group on Tumor Markers (EGTM) status report. Ann Oncol 2010;21(3):441-7.
67. van der Gaag NA, Kloek JJ, de Castro SM, Busch OR, van Gulik TM, Gouma DJ. Preoperative biliary drainage in patients with obstructive jaundice: history and current status. J Gastrointest Surg 2009;13(4):814-20.
68. Eshuis WJ, van der Gaag NA, Rauws EA, et al. Therapeutic delay and survival after surgery for cancer of the pancreatic head with or without preoperative biliary drainage. Ann Surg 2010;252:840-9.
69. Kalser MH, Barkin J, MacIntyre JM. Pancreatic cancer. Assessment of prognosis by clinical presentation. Cancer 1985;56(2):397-402.
70. McKay CJ, Glen P, McMillan DC. Chronic inflammation and pancreatic cancer. Best Pract Res Clin Gastroenterol 2008;22(1):65-73.
71. Pine JK, Fusai KG, Young R, Sharma D, Davidson BR, Menon KV, et al. Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 2009;35(6):605-10.
72. Jamieson NB, Foulis AK, Oien KA, Going JJ, Glen P, Dickson EJ, et al. Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma. Ann Surg 2010;251(6):1003-10.
73. Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 2009;197(4):466-72.
74. Schwarz RE, Keny H. Preoperative platelet count predicts survival after resection of periampullary adenocarcinoma. Hepatogastroenterology 2001;48(41):1493-8.
75. Dominguez I, Crippa S, Thayer SP, Hung YP, Ferrone CR, Warshaw AL, et al. Preoperative platelet count and survival prognosis in resected pancreatic ductal adenocarcinoma. World J Surg 2008;32(6):1051-6.
76. Greene FL, American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag; 2002.
77. Phoa SS, Tilleman EH, van Delden OM, Bossuyt PM, Gouma DJ, Lameris JS. Value of CT criteria in predicting survival in patients with potentially resectable pancreatic head carcinoma. J Surg Oncol 2005;91(1):33-40.
78. Yamaguchi K, Mizumoto K, Noshiro H, Sugitani A, Shimizu S, Chijiiwa K, et al. Pancreatic carcinoma: ≤2 cm versus > 2 cm in size. Int Surg 1999;84(3):213-9.
79. Pongprasobchai S, Pannala R, Smyrk TC, Bamlet W, Pitchumoni S, Ougolkov A, et al. Long-term survival and prognostic indicators in small (≤2 cm) pancreatic cancer. Pancreatology 2008;8(6):587-92.
80. Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001;234(6): 758-68.
81. Wasif N, Ko CY, Farrell J, Wainberg Z, Hines OJ, Reber H, et al. Impact of tumor grade on prognosis in pancreatic cancer: Should we include grade in AJCC staging? Ann Surg Oncol 2010;17(9):2312-20.
82. Couvelard A, O'Toole D, Leek R, Turley H, Sauvanet A, Degott C, et al. Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology 2005;46(6):668-76.
83. Konstantinidis IT, Deshpande V, Zheng H, Wargo JA, Fernandez-del Castillo C, Thayer SP, et al. Does the mechanism of lymph node invasion affect survival in patients with pancreatic ductal adenocarcinoma? J Gastrointest Surg 2010;14(2):261-7.
84. Berger AC, Watson JC, Ross EA, Hoffman JP. The metastatic/ examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2004;70(3):235-40 [discussion 40].
85. Pawlik TM, Gleisner AL, Cameron JL, Winter JM, Assumpcao L, Lillemoe KD, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007;141(5):610-8.
86. Massucco P, Ribero D, Sgotto E, Mellano A, Muratore A, Capussotti L. Prognostic significance of lymph node metastases in pancreatic head cancer treated with extended lymphadenectomy: Not just a matter of numbers. Ann Surg Oncol 2009;16(12):3323-32.
87. Helm J, Centeno BA, Coppola D, Melis M, Lloyd M, Park JY, et al. Histologic characteristics enhance predictive value of American Joint Committee on Cancer staging in resectable pancreas cancer. Cancer 2009;115(18):4080-9.
88. Ishikawa O, Wada H, Ohigashi H, Doki Y, Yokoyama S, Noura S, et al. Postoperative cytology for drained fluid from the pancreatic bed after "curative" resection of pancreatic cancers: Does it predict both the patient's prognosis and the site of cancer recurrence? Ann Surg 2003;238(1):103-10.
89. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007;246(1):52-60.
90. Chang DK, Johns AL, Merrett ND, Gill AJ, Colvin EK, Scarlett CJ, et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 2009;27(17):2855-62.
91. Moutardier V, Giovannini M, Magnin V, Viret F, Lelong B, Delpero JR. How to improve treatment of resectable pancreatic adenocarcinomas? Surgical resection, histopathological examination, adjuvant therapies. Gastroenterol Clin Biol 2004;28(11):1083-91.
92. Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg 2006;93(10):1232-7.
93. Esposito I, Kleeff J, Bergmann F, Reiser C, Herpel E, Friess H, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 2008;15(6):1651-60.
94. Pingpank JF, Hoffman JP, Ross EA, Cooper HS, Meropol NJ, Freedman G, et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg 2001;5(2):121-30.
95. Maire F, Hammel P, Terris B, Paye F, Scoazec JY, Cellier C, et al. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Gut 2002;51(5):717-22.
96. Poultsides GA, Reddy S, Cameron JL, Hruban RH, Pawlik TM, Ahuja N, et al. Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasmassociated invasive adenocarcinoma of the pancreas. Ann Surg 2010;251(3):470-6.
97. Wasif N, Bentrem DJ, Farrell JJ, Ko CY, Hines OJ, Reber HA, et al. Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: A stage-matched comparison of outcomes. Cancer 2010;116(14):3369-77.
98. Garcea G, Neal CP, Pattenden CJ, Steward WP, Berry DP. Molecular prognostic markers in pancreatic cancer: A systematic review. Eur J Cancer 2005;41(15):2213-36.
99. Kim J, Reber HA, Dry SM, Elashoff D, Chen SL, Umetani N, et al. Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. Gut 2006;55(11):1598-605.
100. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321(5897):1801-6.
101. Collisson EA, Mori DD, Hoffmann R, et al. Use of whole genome expression analysis of pancreatic adenocarcinoma to predict prognosis after OXi4503 surgery. J Clin Oncol 2008;26 [abstr 4503].
102. Bartels CL, Tsongalis GJ. MicroRNAs: Novel biomarkers for human cancer. Clin Chem 2009;55(4):623-31.
103. Tonack S, Aspinall-O'Dea M, Neoptolemos JP, Costello E. Pancreatic cancer: Proteomic approaches to a challenging disease. Pancreatology 2009;9(5):567-76.
104. Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009;136(1): 187-95.
105. Kim R, Tan A, Lai KK, Jiang J, Wang Y, Rybicki LA, et al. Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. Cancer 2011;117(14): 3126-34.
106. Ciccolini J, Dahan L, Andre N, Evrard A, Duluc M, Blesius A, et al. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J Clin Oncol 2010;28(1):160-5.